Full Press Release Details
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement.
LXRX
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
Key Takeaway: Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
Price reaction · baseline $2.69 (2022-08-04 close) · hit after-hours · clean, no other LXRX news in the window
day 0 close · peak
+5.2%
day 1
-4.1%
day 3
+3.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus